Smith and Nephew plc (SNN) |
| 31.32 0.98 (3.23%) 06-09 16:00 |
| Open: | 30.87 |
| High: | 31.4 |
| Low: | 30.85 |
| Volume: | 1,356,422 |
| Market Cap: | 13,317(M) |
| PE Ratio: | 21.9 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 36.94 |
| Resistance 1: | 31.63 |
| Pivot price: | 30.34 |
| Support 1: | 30.05 |
| Support 2: | 29.08 |
| 52w High: | 38.79 |
| 52w Low: | 28.4 |
Smith & Nephew plc, along with its various subsidiary companies, operates globally in the research, development, manufacturing, marketing, and distribution of medical devices. The company's orthopedic reconstruction portfolio includes knee implants designed for total knee replacement surgeries and hip implants used in the reconstruction of hip joints. Additionally, they provide trauma and extremity products, which encompass both internal and external fixation devices essential for stabilizing severe bone fractures and correcting skeletal deformities. For surgical practitioners, Smith & Nephew develops sports medicine joint repair solutions. These offerings feature specialized instruments, advanced technologies, and implants crucial for performing minimally invasive procedures on joints. Such procedures address a range of issues, including soft tissue injuries and degenerative conditions affecting the knee, hip, and shoulder, as well as providing systems for meniscal repair. Furthermore, the company supplies arthroscopic enabling technologies. These consist of fluid management systems for surgical access, high-definition cameras, digital image capture devices, endoscopes, light sources, and monitors, all designed to offer enhanced visualization within joints. They also provide radiofrequency, electromechanical, and mechanical tools for tissue resection, alongside hand instruments for the removal of damaged tissue. Additionally, Smith & Nephew offers ear, nose, and throat (ENT) solutions. In the realm of wound management, Smith & Nephew provides an extensive range of advanced wound care products intended for both the treatment and prevention of acute and chronic wounds. This category covers conditions such as leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Their advanced wound bioactives division includes biologics and other biologically active technologies vital for debridement and promoting dermal repair and regeneration. This also extends to regenerative medicine products, such as substitutes for skin, bone grafts, and articular cartilage. Completing their wound care offerings are advanced wound devices, including traditional and single-use negative pressure wound therapy systems and hydrosurgery systems. The primary customer base for Smith & Nephew plc consists of healthcare providers worldwide. Founded in 1856, the company's corporate headquarters are situated in Watford, United Kingdom.
| EPS | 1.430 |
| Book Value | 2.490 |
| PEG Ratio | 1.20 |
| Gross Profit | 9.908 |
| Profit Margin (%) | 10.14 |
| Operating Margin (%) | 13.99 |
| Return on Assets (ttm) | 5.3 |
| Return on Equity (ttm) | 11.8 |
Tue, 09 Jun 2026
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
Tue, 09 Jun 2026
Smith & Nephew plc (SNN) Shareholder/Analyst Call - Slideshow (NYSE:SNN) 2026-06-09 - Seeking Alpha
Mon, 08 Jun 2026
Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Exploring a Potential 14.32% Upside for Investors - DirectorsTalk Interviews
Mon, 08 Jun 2026
Handheld robot assists first shoulder and knee replacements at Duke, NYU - Stock Titan
Fri, 05 Jun 2026
Cevian Capital II GP LTD Increases Stake in Smith & Nephew PLC - GuruFocus
Thu, 04 Jun 2026
Smith & Nephew PLC (SNN) Stock Up 3.1% and Still Undervalued -- GF Score: 86/100 - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |